SARC041

July 26, 2021

Phase 3 Randomized Double-Blind Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma

TYPE OF SARCOMA: Advanced Dedifferentiated Liposarcoma
DRUG: Abemaciclib

ACCRUAL STATUS: Now recruiting for patients

OVERALL STUDY PRINCIPAL INVESTIGATOR:
Mark Dickson, MD
Memorial Sloan Kettering Cancer Center

CLINICALTRIALS.GOV IDENTIFIER: NCT04967521 

FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV

To learn more about this study view Dr. Dickson’s SARC041 presentation at the 2021 SARC Semiannual Meeting:

To contact the study research staff:

contact sarc
Back to top